Vaxcyte Reports Positive Phase 3 Vaccine Results
The company’s VAX-31 candidate met all primary immunogenicity goals in a pivotal trial for adults 50 and older.
Updated on Oct. 30, 2026 in COVID-19
Live Poll
Do you trust that newer, broader-coverage vaccines provide better protection against disease than current options?
On October 5, 2026, Vaxcyte reported positive topline results from the phase 3 OPUS-1 clinical trial, showing its VAX-31 vaccine candidate met all prespecified primary end points. The study involved adults aged 50 and older and demonstrated the candidate's noninferiority and superiority across multiple serotypes compared to existing options.
Why it matters
Current pneumococcal vaccines fail to protect against certain serotypes, leaving some adults at continued risk for disease. VAX-31 utilizes site-specific conjugation technology designed to provide broader coverage while maintaining strong immune responses.
The study met primary immunogenicity end points for all 28 shared serotypes in participants aged 50 and older. Results confirmed four unique serotypes met superiority criteria for VAX-31, while no serious vaccine-related adverse events were reported.
The players
Vaxcyte
A biotechnology company focused on developing novel vaccines to prevent infectious diseases through its proprietary site-specific conjugation technology.
The details
The pivotal OPUS-1 trial randomized participants to receive a single dose of VAX-31, PCV21, or PCV20. VAX-31 is a 31-valent vaccine, and across all three trials, approximately 3500 of the 6189 enrolled participants received the VAX-31 candidate.
Timeline
October 5, 2026: Topline results from the pivotal OPUS-1 trial were released.
October 21-24, 2026: Study design was presented at the IDWeek 2026 conference.
First half of 2027: Expected results from the OPUS-2 and OPUS-3 trials.
First half of 2028: Planned submission of a Biologics License Application.
Health Landscape
This development represents a significant shift in pneumococcal protection by expanding vaccine valency beyond the current standards set by existing products. The results validate the platform's utility as it moves toward the FDA's Biologics License Application process for final regulatory review.
The success of this trial suggests a potential future option for adults to gain broader protection against pneumococcal disease with a single dose. Patients may eventually see improved coverage against more serotypes than what is currently provided by existing market vaccines.
The takeaway
Advancements in vaccine technology like site-specific conjugation are actively closing gaps in disease protection for older adults. Individuals should discuss their current vaccination status with healthcare providers to understand how evolving product valency may impact their long-term health.
What happens next
Vaxcyte expects to release results from the OPUS-2 and OPUS-3 clinical trials in the first half of 2027, followed by a formal Biologics License Application submission in the first half of 2028.
Further reading
For more on evolving immunization strategies, see COVID-19.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust that newer, broader-coverage vaccines provide better protection against disease than current options?
